



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|---|---|
| (51) International Patent Classification ⁷ : C07D 233/24, A61K 31/417, A61P 43/00, C07D 409/12, 403/12, 401/12, 405/12, 413/12, 417/12 | | A1 | (11) International Publication Number: WO 00/66563 |
| | | | (43) International Publication Date: 9 November 2000 (09.11.00) |
| (21) International Application Number: PCT/EP00/03848 | | <p>(74) Agent: LEAROYD, Stephanie, A.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> | |
| (22) International Filing Date: 28 April 2000 (28.04.00) | | | |
| (30) Priority Data: 9910110.7 30 April 1999 (30.04.99) GB | | | |
| (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB] ; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): (BIGHAM, Eric , Cleveland [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US); (BISHOP, Michael , Joseph [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US); (DREWRY, David , Harold [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US); (GARRISON, Deanna , Trojan [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US); (HODSON, Stephen , Joseph [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US); (NAVAS III, Frank [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). | | | |
| | | <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> | |

(54) Title: IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS



(57) Abstract

Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Formula (i) wherein R^2 , R^3 , R^4 and R^5 are independently H, halogen, $-\text{OH}$, $-\text{C}_1$ -alkyl, $-\text{C}_1$ -alkoxy, $-\text{SC}_1$ -alkyl, or $-\text{CF}_3$, with the proviso that at least 2 of R^2 , R^3 , R^4 and R^5 are H; R^6 is H or $-\text{CH}_3$; R^1 is $-\text{S}(\text{O})_n\text{R}^7$ where n is 1 or 2, $-\text{S}(\text{O})_2\text{NHR}^8$, $-\text{C}(\text{O})\text{R}^9$, $-\text{NR}^{14}\text{R}^{15}$, $-\text{C}(\text{R}^{17})=\text{NOR}^{16}$, (a) or a 5, 6, or 7 membered heteroalkyl or heteroaryl group optionally substituted. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.

EXPRESS MAIL LABEL
NO. EL395943218US